• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Tokai Journal of Experimental and Clinical Medicine >Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia
【24h】

Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia

机译：抗胆固醇治疗对慢性卒中高脂血症患者可溶性ICAM-1的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: We examined the effects of drug therapy with pravastatin (P) or bezafibrate (B) and diet (D) therapy on serum lipids and soluble intercellular adhesion molecule-1 (sICAM-1) in hyperlipidemic cerebrovascular disease (CVD) patients in the chronic stage. Methods: This study included 36 patients (28 with cerebral infarction and hyperlipidemia and eight with cerebral hemorrhage and hyperlipidemia) divided into three groups: Group P (12 patients), Group B (10 patients), and Group D (14 patients). Before and after treatment, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and sICAM-1 levels were measured. Results: In Group P, Group B and Group D, TC levels were decreased by 30% (p < 0.005), 21% (p < 0.01), and 21% (p < 0.001), LDL-C levels were decreased by 38% (p < 0.005), 18% (not significant), and 25% (p < 0.005) and TG levels were decreased by 27% (p < 0.05), 53% (p < 0.005) and 22% (p < 0.05), respectively. sICAM-1 levels were decreased by 20% (p < 0.005) in Group P, but were not decreased in Group B or Group D. There was no correlation between ΔTC and Δ sICAM-1 (r = 0.172). Conclusion: Administration of pravastatin significantly reduced sICAM-1 levels, independently of its decreasing effect on TC and TG in chronic CVD patients. Pravastatin may exert anti-atherosclerotic activity via two distinct mechanisms.
机译：目的：我们研究了普伐他汀（P）或苯扎贝特（B）和饮食（D）药物治疗对高脂血症性脑血管病（CVD）患者血清脂质和可溶性细胞间粘附分子1（sICAM-1）的影响。慢性期。方法：本研究包括36例患者（28例脑梗死和高脂血症，8例脑出血和高脂血症），分为三组：P组（12例），B组（10例）和D组（14例）。治疗前后分别测量总胆固醇（TC），低密度脂蛋白胆固醇（LDL-C），甘油三酸酯（TG），高密度脂蛋白胆固醇（HDL-C）和sICAM-1水平。结果：在P组，B组和D组中，TC水平分别降低了30％（p <0.005），21％（p <0.01）和21％（p <0.001），降低了38 ％（p <0.005），18％（不显着）和25％（p <0.005）和TG水平分别降低了27％（p <0.05），53％（p <0.005）和22％（p <0.05） ）， 分别。 P组的sICAM-1水平降低了20％（p <0.005），而B组或D组的sICAM-1水平没有下降。ΔTC和ΔsICAM-1之间没有相关性（r = 0.172）。结论：普伐他汀的给药可显着降低sICAM-1水平，而与降低sICAM-1对慢性CVD患者的TC和TG的影响无关。普伐他汀可能通过两种不同的机制发挥抗动脉粥样硬化活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号